Anti-Siglec antibody, pharmaceutical composition comprising the same, and uses thereof
US12103969B2 · kind B2 · utility
0Cited by
0References
10Claims
0Family size
Assignee
Inventors
Key dates
| Filing date | Sep 25, 2018 |
| Grant date | Oct 1, 2024 |
| Priority date | — |
| Expiry date | Dec 22, 2040 |
Classification
- Technology area (CPC C)Chemistry; Metallurgy
- CPC primaryC07K2317/77
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
Disclosed herein is a novel monoclonal antibody exhibiting binding affinity to Siglec-3 receptor. According to the embodiment, the monoclonal antibody is capable of reversing HBV-induced immunosuppression. Accordingly, also disclosed herein are the uses thereof in the treatment and/or prophylaxis of hepatitis B virus (HBV) infection.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.